相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Chronic Empagliflozin Treatment Reduces Myocardial Infarct Size in Nondiabetic Mice Through STAT-3-Mediated Protection on Microvascular Endothelial Cells and Reduction of Oxidative Stress
Panagiota Efstathia Nikolaou et al.
ANTIOXIDANTS & REDOX SIGNALING (2021)
Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells
Laween Uthman et al.
CARDIOVASCULAR DRUGS AND THERAPY (2021)
Canagliflozin impedes ischemic hind-limb recovery in the setting of diabetes
Margaret Nalugo et al.
VASCULAR MEDICINE (2021)
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Volker Vallon et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 83 (2021)
Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial
Naoto Katakami et al.
CARDIOVASCULAR DIABETOLOGY (2021)
The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1β and IL-18 secretion
Sergiy Sukhanov et al.
CELLULAR SIGNALLING (2021)
Empagliflozin restores chronic kidney disease-induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction
Rio P. Juni et al.
KIDNEY INTERNATIONAL (2021)
Role of Canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes
Seshagiri Rao Nandula et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: protective effect of gliflozins
Sin-Hee Park et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial
Andrei C. Sposito et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Inhibition of SGLT2 Rescues Bone Marrow Cell Traffic for Vascular Repair: Role of Glucose Control and Ketogenesis
Mattia Albiero et al.
DIABETES (2021)
Sodium Glucose Co-Transporter 2 Inhibitors Ameliorate Endothelium Barrier Dysfunction Induced by Cyclic Stretch through Inhibition of Reactive Oxygen Species
Xiaoling Li et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics
Zhenghong Liu et al.
THERANOSTICS (2021)
Angiotensin II-induced redox-sensitive SGLT1 and 2 expression promotes high glucose-induced endothelial cell senescence
Sonia Khemais-Benkhiat et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Effect of tofogliflozin on cardiac and vascular endothelial function in patients with type 2 diabetes and heart diseases: A pilot study
Mayu Tochiya et al.
JOURNAL OF DIABETES INVESTIGATION (2020)
Effect of empagliflozin on brachial artery shear stress and endothelial function in subjects with type 2 diabetes: Results from an exploratory study
Concetta Irace et al.
DIABETES & VASCULAR DISEASE RESEARCH (2020)
The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension
Biswajit Chowdhury et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat
Sin-Hee Park et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Canagliflozin impairs blood reperfusion of ischaemic lower limb partially by inhibiting the retention and paracrine function of bone marrow derived mesenchymal stem cells
Yinuo Lin et al.
EBIOMEDICINE (2020)
Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice
Byambasuren Ganbaatar et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
Empagliflozin attenuates neointimal hyperplasia after drug-eluting-stent implantation in patients with type 2 diabetes
Takehiro Hashikata et al.
HEART AND VESSELS (2020)
Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment
Ignatios Ikonomidis et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: Role of heme oxygenase-1
Ghazaleh Behnammanesh et al.
REDOX BIOLOGY (2020)
Dapagliflozin Promotes Neovascularization by Improving Paracrine Function of Skeletal Muscle Cells in Diabetic Hindlimb Ischemia Mice Through PHD2/HIF-1α Axis
Dyah Ari Nugrahaningrum et al.
FRONTIERS IN PHARMACOLOGY (2020)
Empagliflozin's Ameliorating Effect on Plasma Triglycerides: Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease
Takahiro Sawada et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2020)
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Martin R. Cowie et al.
NATURE REVIEWS CARDIOLOGY (2020)
Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study
Kazuomi Kario et al.
JOURNAL OF CLINICAL HYPERTENSION (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Anti-inflammatory effects of sodium-glucose co-transporter 2 inhibitors on atherosclerosis
Yingxiu Kang et al.
VASCULAR PHARMACOLOGY (2020)
Global trends in diabetes complications: a review of current evidence
Jessica L. Harding et al.
DIABETOLOGIA (2019)
SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob-/- mice
Damilola D. Adingupu et al.
CARDIOVASCULAR DIABETOLOGY (2019)
How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial
Agnes Bosch et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Empagliflozin restores the integrity of the endothelial glycocalyx in vitro
Scott Cooper et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
Ghazaleh Behnammanesh et al.
FRONTIERS IN PHARMACOLOGY (2019)
Smooth Muscle Cell Phenotypic Diversity At the Crossroads of Lineage Tracing and Single-Cell Transcriptomics
Mingjun Liu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
Canagliflozin for Japanese patients with chronic heart failure and type II diabetes
Akira Sezai et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Ipragliflozin-induced adipose expansion inhibits cuff-induced vascular remodeling in mice
Kentaro Mori et al.
CARDIOVASCULAR DIABETOLOGY (2019)
The Effects of Dapagliflozin on Systemic and Renal Vascular Function Display an Epigenetic Signature
Anna Solini et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Effects of ticagrelor, empagliflozin and tamoxifen against experimentally-induced vascular reactivity defects in rats in vivo and in vitro
Yasmin Moustafa Ahmed et al.
PHARMACOLOGICAL REPORTS (2019)
SGLT-2 (Sodium-Glucose Cotransporter 2) Inhibition Reduces Ang II (Anciotensin II)-Induced Dissecting Abdominal Aortic Aneurysm in ApoE (Apolipoprotein E) Knockout Mice
Rebeca Ortega et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
Effect of Empagliflozin on Endothelial Function in Patients With Type 2 Diabetes and Cardiovascular Disease: Results from the Multicenter, Randomized, Placebo-Controlled, Double-Blind EMBLEM Trial
Atsushi Tanaka et al.
DIABETES CARE (2019)
Vascular Endothelial Cell Biology: An Update
Anne Krueger-Genge et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Luseogliflozin attenuates neointimal hyperplasia after wire injury in high-fat diet-fed mice via inhibition of perivascular adipose tissue remodeling
Yusaku Mori et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Central artery stiffness and thoracic aortopathy
J. D. Humphrey et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cardiac Microvascular Endothelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and Restored by Empagliflozin
Rio P. Juni et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2019)
Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake
Kosuke Kaji et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice
Dustin M. Lee et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Arterial smooth muscle dynamics in development and repair
Urmas Roostalu et al.
DEVELOPMENTAL BIOLOGY (2018)
Economic Costs of Diabetes in the US in 2017
Wenya Yang et al.
DIABETES CARE (2018)
The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus
Seigo Sugiyama et al.
INTERNAL MEDICINE (2018)
The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels
Hongliang Li et al.
LIFE SCIENCES (2018)
Endothelial cell dysfunction and glycocalyx - A vicious circle
Xiaohui Zhang et al.
MATRIX BIOLOGY (2018)
Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress
Mahmoud El-Daly et al.
VASCULAR PHARMACOLOGY (2018)
Canagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I: an off-target adverse effect
Philipp F. Secker et al.
CELL DEATH & DISEASE (2018)
Canagliflozin inhibits interleukin-1 beta-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms
Sarah J. Mancini et al.
SCIENTIFIC REPORTS (2018)
Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission
Hao Zhou et al.
REDOX BIOLOGY (2018)
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
Tricia Santos Cavaiola et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2018)
Glutaminase-1 stimulates the proliferation, migration, and survival of human endothelial cells
Kelly J. Peyton et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
Annayya R. Aroor et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Effects of SGLT2 Inhibitors on Circulating Stem and Progenitor Cells in Patients With Type 2 Diabetes
Benedetta Maria Bonora et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus
Mojca Lunder et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Canagliflozin Improves the Recovery of Blood Flow in an Experimental Model of Severe Limb Ischemia
Stephen E. Sherman et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2018)
Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation
Laween Uthman et al.
DIABETOLOGIA (2018)
Phlorizin Exerts Direct Protective Effects on Palmitic Acid (PA)-Induced Endothelial Dysfunction by Activating the PI3K/AKT/eNOS Signaling Pathway and Increasing the Levels of Nitric Oxide (NO)
Chun-Ying Li et al.
MEDICAL SCIENCE MONITOR BASIC RESEARCH (2018)
Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis
Tracey Gaspari et al.
DIABETES & VASCULAR DISEASE RESEARCH (2018)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
VASCULAR SMOOTH MUSCLE CELLS AND ARTERIAL STIFFENING: RELEVANCE IN DEVELOPMENT, AGING, AND DISEASE
Patrick Lacolley et al.
PHYSIOLOGICAL REVIEWS (2017)
Comparison of very long-term clinical and angiographic outcomes of bare metal stent implants between patients with and without type 2 diabetes
Cheng-Hui Lu et al.
PRIMARY CARE DIABETES (2017)
The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
Sebastian Steven et al.
REDOX BIOLOGY (2017)
AFM-based detection of glycocalyx degradation and endothelial stiffening in the db/db mouse model of diabetes
Marta Targosz-Korecka et al.
SCIENTIFIC REPORTS (2017)
Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study
Anna Solini et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Glutamine fuels proliferation but not migration of endothelial cells
Boa Kim et al.
EMBO JOURNAL (2017)
Role of glutamine and interlinked asparagine metabolism in vessel formation
Hongling Huang et al.
EMBO JOURNAL (2017)
Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study
Fumika Shigiyama et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis
Michael Pfeifer et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Vitamin D Receptor Activation Reduces Angiotensin-II-Induced Dissecting Abdominal Aortic Aneurysm in Apolipoprotein E-Knockout Mice
Sara Martorell et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)
Vascular endothelium - Gatekeeper of vessel health
Paul A. Cahill et al.
ATHEROSCLEROSIS (2016)
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
Ele Ferrannini et al.
DIABETES (2016)
The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels
Simon A. Hawley et al.
DIABETES (2016)
The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration
Linda A. Villani et al.
MOLECULAR METABOLISM (2016)
Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse
Hotimah Masdan Salim et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2016)
SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery
Ying Han et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2015)
Central Role of eNOS in the Maintenance of Endothelial Homeostasis
Christian Heiss et al.
ANTIOXIDANTS & REDOX SIGNALING (2015)
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
R. Chilton et al.
DIABETES OBESITY & METABOLISM (2015)
Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes
Rodney A. Hayward et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Vascular stiffness in insulin resistance and obesity
Guanghong Jia et al.
FRONTIERS IN PHYSIOLOGY (2015)
Inhibition of Human UDP-Glucuronosyltransferase Enzymes by Canagliflozin and Dapagliflozin: Implications for Drug-Drug Interactions
Attarat Pattanawongsa et al.
DRUG METABOLISM AND DISPOSITION (2015)
Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1
Gnanapragasam Arunachalam et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
David Z. I. Cherney et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
Bowen Lin et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Arterial Stiffness as a Risk Factor for Coronary Artery Disease
Josh Liao et al.
CURRENT ATHEROSCLEROSIS REPORTS (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity
Matthias Oelze et al.
PLOS ONE (2014)
A Ligand-Independent VEGFR2 Signaling Pathway Limits Angiogenic Responses in Diabetes
Carmen M. Warren et al.
SCIENCE SIGNALING (2014)
Arterial Stiffness: A Nexus between Cardiac and Renal Disease
Guanghong Jia et al.
CARDIORENAL MEDICINE (2014)
Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology
Sanjay Kalra
DIABETES THERAPY (2014)
Importance of endothelial NF-kappa B signalling in vascular remodelling and aortic aneurysm formation
Tokuo Saito et al.
CARDIOVASCULAR RESEARCH (2013)
All-Cause and Cardiovascular Mortality in Middle-Aged People With Type 2 Diabetes Compared With People Without Diabetes in a Large UK Primary Care Database
Kathryn S. Taylor et al.
DIABETES CARE (2013)
Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance
Annayya R. Aroor et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2013)
Vascular Remodeling in Hypertension Mechanisms and Treatment
Ernesto L. Schiffrin
HYPERTENSION (2012)
Compound C Inhibits Vascular Smooth Muscle Cell Proliferation and Migration in an AMP-Activated Protein Kinase-Independent Fashion
Kelly J. Peyton et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Dose-Dependent Modulatory Effects of Insulin on Glucose-Induced Endothelial Senescence In Vitro and In Vivo: A Relationship between Telomeres and Nitric Oxide
Hisako Matsui-Hirai et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Arterial Stiffness and Cardiovascular Events The Framingham Heart Study
Gary F. Mitchell et al.
CIRCULATION (2010)
Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus
L. N. Broekhuizen et al.
DIABETOLOGIA (2010)
The global burden of diabetes and its complications: an emerging pandemic
Susan van Dieren et al.
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION (2010)
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
N. Sarwar et al.
LANCET (2010)
Molecular Insights and Therapeutic Targets for Diabetic Endothelial Dysfunction
Jian Xu et al.
CIRCULATION (2009)
Vascular endothelial senescence: from mechanisms to pathophysiology
Jorge D. Erusalimsky
JOURNAL OF APPLIED PHYSIOLOGY (2009)
Recovery from hind limb ischemia is less effective in type 2 than in type 1 diabetic mice: Roles of endothelial nitric oxide synthase and endothelial progenitor cells
Jinglian Yan et al.
JOURNAL OF VASCULAR SURGERY (2009)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes
Christian Rask-Madsen et al.
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2007)
Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo
M Nieuwdorp et al.
DIABETES (2006)
Angiogenic and Antiangiogenic Factors in Proliferative Diabetic Retinopathy
Rafael Simo et al.
CURRENT DIABETES REVIEWS (2006)
Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients
NEJ West et al.
CIRCULATION (2004)
Prevention and reversal of premature endothelial cell senescence and vasculopathy in obesity-induced diabetes by ebselen
SV Brodsky et al.
CIRCULATION RESEARCH (2004)
Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies
VJ Dzau et al.
NATURE MEDICINE (2002)
Diabetes and atherosclerosis - Epidemiology, pathophysiology, and management
JA Beckman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Human vascular smooth muscle cells of diabetic origin exhibit increased proliferation, adhesion, and migration
PL Faries et al.
JOURNAL OF VASCULAR SURGERY (2001)
Endothelial dysfunction in diabetes
AS De Vriese et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
分享论文
